| CTRI Number |
CTRI/2025/02/080065 [Registered on: 07/02/2025] Trial Registered Prospectively |
| Last Modified On: |
05/02/2025 |
| Post Graduate Thesis |
No |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug Biological |
| Study Design |
Randomized, Parallel Group, Multiple Arm Trial |
|
Public Title of Study
|
Trial of Immuno modulatory drugs in TBM |
|
Scientific Title of Study
|
Randomized Trial of Thalidomide and Infliximab in Paradoxical Worsening in Patients of Tuberculous Meningitis (TBM): A Clinical, Radiological and Biomarker based Study |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Manish Modi |
| Designation |
Professor |
| Affiliation |
PGIMER |
| Address |
Deapartment of Neurology,
PGIMER, Sector 12,
CHANDIGARH SECTOR 12,
CHANDIGARH Chandigarh CHANDIGARH 160012 India |
| Phone |
9876197533 |
| Fax |
01722744401 |
| Email |
modipgi@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Manish Modi |
| Designation |
Professor |
| Affiliation |
PGIMER |
| Address |
Deapartment of Neurology,
PGIMER, Sector 12,
CHANDIGARH SECTOR 12,
CHANDIGARH Chandigarh CHANDIGARH 160012 India |
| Phone |
9876197533 |
| Fax |
01722744401 |
| Email |
modipgi@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
Manish Modi |
| Designation |
Professor |
| Affiliation |
PGIMER |
| Address |
Deapartment of Neurology,
PGIMER, Sector 12,
CHANDIGARH SECTOR 12,
CHANDIGARH Chandigarh CHANDIGARH 160012 India |
| Phone |
9876197533 |
| Fax |
01722744401 |
| Email |
modipgi@gmail.com |
|
|
Source of Monetary or Material Support
|
| ICMR, V. Ramalingaswami Bhawan, P.O. Box No. 4911
Ansari Nagar, New Delhi - 110029, India |
|
|
Primary Sponsor
|
| Name |
ICMR New Delhi INDIA |
| Address |
V. Ramalingaswami Bhawan,
Ansari Nagar,
New Delhi - 110029,
India |
| Type of Sponsor |
Government funding agency |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Manish Modi |
PGIMER, CHANDIGARH, INDIA |
Department of Neurology,
Ground Floor, A Block, Room no. 7, Nehru Hospital Building,
PGIMER,
Chandigarh-160012, INDIA Chandigarh CHANDIGARH |
9876197533
modipgi@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Institutional Ethics Committee, PGIMER, Chandigarh |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: A179||Tuberculosis of nervous system, unspecified, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Comparator Agent |
Infliximab |
Infliximab will be given intravenously as infusion in a dose of 5mg/kg/ month for 3-6 months
|
| Intervention |
Thalidomide |
Thalidomide will be given orally in a dose of 3mg/kg body weight per day for 3 months and then gradually tapered off over 3 months |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
80.00 Year(s) |
| Gender |
Both |
| Details |
1. Age 18 years or more
2. Confirmed cases of CNS TB with Paradoxical response based on clinical, biochemical (CSF) and radiological imaging.
3. Willingness to participate in the study.
|
|
| ExclusionCriteria |
| Details |
1. Patients less than 18 years
2. Patients having MDR TB.
3. Patients in whom the symptoms were better explained by some other cause as per abnormalities in the investigations performed
4. Patients not willing to give written informed consent or Assent
5. Other similar diseases mimicking TBM like fungal infections, etc.
6. Pregnancy
7. Patients with HIV |
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
|
Method of Concealment
|
Other |
|
Blinding/Masking
|
Investigator Blinded |
|
Primary Outcome
|
| Outcome |
TimePoints |
| To study the clinical outcome in patients of CNS TB with paradoxical response |
Baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| 1. To study the radiological outcome on follow up along with clinical parameters |
At end of 3 months, 6 months and completion of therapy |
| 2. To study cytokine levels in CSF and Blood at time of recruitment and Changes in blood on follow up after 3 months |
At Baseline and at 3 months |
|
|
Target Sample Size
|
Total Sample Size="198" Sample Size from India="198"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
Phase 3/ Phase 4 |
|
Date of First Enrollment (India)
|
20/02/2025 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="3" Months="0" Days="0" |
|
Recruitment Status of Trial (Global)
|
Open to Recruitment |
| Recruitment Status of Trial (India) |
Open to Recruitment |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Patients with Diagnosed Tuberculous Meningitis can paradoxically worsen after starting Antitubercular Treatment (ATT) and steroids. Paradoxical worsening manifests as vision loss, myelopathy, cranial nerve deficits, and hydrocephalus, due to arachnoiditis. We are proposing TBM as both a paucibacillary infectious and Immunological disorder, which needs stronger immunomodulation in patients with paradoxical responses. With this background, all patients who fulfill Marais’s criteria for TBM, already being followed up every month in the TBM Clinic of PGIMER, Chandigarh will be assessed for paradoxical worsening. After confirming radiologically, these patients will be subjected to CSF analysis to rule out MDR TB or alternate infections and assess cytokine levels in CSF and serum. All the cases will be evaluated independently by 2 Neurologists with experience in Neuro infections and 1 infectious disease expert. Diagnosis of paradoxical worsening will be reached by consensus. Thereafter, these patients will be randomized to Thalidomide or Infliximab arm vs standard care (Steroids). All patients will be followed up monthly for any complications till the completion of therapy. However, repeat radiological, and biomarkers (TNF alpha, VEGF, IL-6, and IL-10) responses will be measured at 3 months. The outcome of the three groups will be analyzed at the end of the study. If required, an interim analysis will be done. |